High-throughput genomic and proteomic approaches to the study of the interaction between androgen–AR axis and the EMT pathway with cancer stemness may reveal the novel molecular mechanism underlying PTC tumorigenesis and provide useful information to find new therapeutic targets in thyroid cancers. The gene discussed is AR; the disease is thyroid gland carcinoma.